+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Clinical Scholar Award in CLL

CLL Society

Introduction: CLL Society is pleased to announce a funding opportunity for exceptional physician researchers who have already established themselves in the field of CLL/SLL. This Award is designed to support the research efforts of an advanced physician scientist who is engaged in independent clinical research and has demonstrated exceptional leadership, scholarship, and academic success.

Award Amount: CLL Society’s 2026 Clinical Scholar Award is $300,000 which will be distributed in three annual payments of $100,000. The first $100,000 will be paid within 30 days of the effective date, the second $100,000 will be paid within 30 days after CLL Society’s approval of the first submitted annual Scientific Progress Report and Financial Report. The final $100,000 will be paid within 30 days after CLL Society’s approval of the second annual Scientific Progress Report and Financial Report.

Goal: The Clinical Scholar Award is intended to advance the development of treatment and/or preventative options that lead to a higher quality of life for those living with CLL and SLL, while continuing to support the careers of established physician scientists.

Budget: Funding should be used to support the Awardee’s time through salary support, with a maximum allowable institutional overhead of 10%. Major equipment is not allowed, and no overhead will be provided for outside institutions. Funding is intended to cover the research rather than administrative costs. We encourage applicants to work with their institutions to reduce administrative costs so that the maximum amount of the award can be used for the research project. Travel expenses are allowed for no more than one hematology/oncology meeting per year up to $2,500. The estimated funding period is July 1st, 2026, to June 30th, 2029.

AI Based Application Success Predictor

1. Strong, Explicit Focus on CLL/SLL

The #1 predictor of success is a proposal that directly and exclusively addresses CLL or SLL.

Top-aligned topics include:

New therapeutic targets or combination strategies

Resistance mechanisms (e.g., to BTKi, venetoclax)

Immunotherapy (CAR-T, NK cells, immune evasion)

Minimal residual disease (MRD) detection technologies

Biomarkers for prognosis or response

Real-world outcomes or toxicity management

Treatment sequencing in the BTKi/venetoclax era

❗ If the proposal is not clearly and explicitly CLL-focused, it is unlikely to be funded.

2. Alignment With the Specific Grant Mechanism

CLL Society offers grants such as:

🔹 Research Grants (1–2 years)

Focused on innovative scientific advances.

Require preliminary data showing feasibility.

🔹 Young Investigator Awards

Target early-career leukemia/CLL researchers.

Strong mentorship and training plan essential.

🔹 Quality-of-Life / Supportive Care Grants

Focus on patient-centered needs: symptom burden, mental health, survivorship, financial toxicity, access to care.

🔹 Collaborative or Data Sharing Projects

Multi-site collaborations strongly favored.

Use of large datasets or real-world evidence encouraged.

Predictor: Match your career stage, project scope, and objectives to the correct program.

3. High Innovation with Clear Patient Impact

The CLL Society strongly values proposals that will change patient outcomes, not incremental science.

Strong predictors:

Novel mechanism-of-action therapeutics

AI/ML for prognosis or MRD tracking

First-in-field biomarker strategies

Rapid translation toward clinical trial feasibility

Interventions that improve patient quality of life or reduce disparities

Predictor: "How will this improve the lives of CLL patients?" must be clearly answered.

4. Strong Preliminary Data

Even for early-career grants, successful proposals typically include:

Pilot data supporting the hypothesis

Proof-of-concept for a new method or assay

Feasibility evidence (cell lines, patient samples, computational models)

Predictor: Show that the project is ready to run, not exploratory speculation.

5. Use of Human Samples, Registry Data, or Clinically Relevant Models

CLL Society values clinically anchored research:

Primary CLL samples

CLL mouse models or PDX systems

MRD monitoring platforms

Real-world datasets

CLL patient registries

Predictor: Human relevance = stronger impact score.

6. Strong Mentorship & Environment (Especially for Young Investigators)

Winning applicants often have:

A mentor with a track record in CLL or hematologic malignancies

A formal training plan

Institutional commitment (protected time, access to biobanks, cores, sequencing, etc.)

Predictor: A supportive environment increases reviewer confidence.

7. Collaboration Is a Major Strength

CLL is a rare blood cancer, so collaborative research is highly valued.

Competitive proposals often include:

Multi-institutional teams

Clinical + basic + computational science integration

Partnerships with patient advocacy or community oncology sites

Predictor: Multi-PI, multi-center frameworks score higher.

8. Clear, Feasible Aims and Timeline

CLL Society funding is usually 1–2 years.

Projects must be:

Clearly scoped

Milestone-driven

Feasible within the timeframe

Logically structured (Aim 1 → Aim 2 → translational step)

Predictor: Feasibility is a major review criterion.

9. Emphasis on Patient-Centered Outcomes (for QoL Grants)

Quality-of-life proposals should target:

Fatigue, anxiety, depression

Infections and immune dysfunction

Financial toxicity

Caregiver burden

Racial/ethnic disparities

Decision-making and health literacy

Predictor: Show real-world relevance and rapid benefit to the CLL patient community.

10. Clear, Persuasive, Reviewer-Friendly Writing

High-scoring proposals:

Clearly state the problem, gap, and solution

Use figures for preliminary data

Provide a compelling rationale

Are easy for both clinicians and basic scientists to follow

Predictor: Good storytelling and clarity significantly improve reviewer enthusiasm.

🏆 Summary Table

Predictor	Why It Matters
CLL/SLL-specific focus	CLL Society funds ONLY CLL-targeted work
Mechanism alignment	Ensures reviewer expectations match project & career stage
Innovation + impact	CLL Society wants transformative advances
Preliminary data	Demonstrates feasibility
Human-relevant models	Strengthens translational value
Mentorship & environment	Critical for early investigators
Collaboration	Preferred for rare-disease research
Feasible, focused aims	Increases deliverability
Patient-centered framework	Key for QoL and survivorship proposals
Strong writing	Improves review scores

Specialties

Clinical Trials

Neurosciences

Eligibility Requirements

Applicants must review CLL Society’s general eligibility criteria which are located on the website here. This grant does allow for concurrently held research awards from other non-profit organizations or government institutions on a case-by-case basis. Applicants must provide documentation of current and pending support within the application. Eligible applicants must currently be practicing at an accredited academic clinical research institution located within the United States and perform their research at that institution for the duration of the award. US citizenship is not required, but the research itself must be conducted in the United States.

Cancer center directors should not apply for the Clinical Scholar Award and contact Principal Investigators on P-series grants (i.e., P01, P02, P30, P50) are ineligible.

In addition to CLL Society’s general eligibility criteria, Clinical Scholar Award applicants must:

• Be an MD, DO, or the equivalent.

• Be an independent clinician investigator who is mid-stage in their career with a strong focus on CLL research and/or treatment. Mid-stage independent clinician investigators are defined by CLL Society’s Research Program as being someone who is either an associate professor, or within five years or less from acquiring full professorship as of the funding date of July 1st, 2026.

• Be an established career physician researcher in the field of CLL as evidenced by having received some prior funding (examples may include R01 funding or mid-career awards from LLS or the DOD) and they must possess a broad knowledge of the disease.

• Currently spend 30% or more of their time on basic, translational, or clinical research efforts in their current position, but still have direct patient contact and clinical responsibilities in their role.

Sponsor Details

Sponsor Institute/Organizations: CLL Society

Sponsor Type: Corporate/Non-Profit

Address: 450 Rev Kelly M Smith Way Nashville, TN 37203

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity